Table 3.
Kumamoto | UKPDS 33 |
UKPDS 34 |
VA Diabetes Feasibility Trial |
ACCORD | ADVANCE | VADT | |
---|---|---|---|---|---|---|---|
Median length of follow-up (yrs) | 6 | 10 | 10.7 | 2 | 5 | 5 | 6 |
Microalbuminuria | 15.6% | 21.0%* | 23% | 44% | 23.5% | 24.7% | 11.5% |
Macroalbuminuria | 3.9% | 5.0%* | … | 8.5% | 4.6% | 3.5% | 4.0% |
Doubling of Creatinine | … | 1.0%* | … | … | 7.4% | 1.1% | 8.8% |
ESRD | … | 0.6%† | 0.5% | … | 2.8% | 0.5% | 1.0% |
Death from Renal Failure | … | 0.3%† | 0.4% | … | … | 0.5% | … |
At 9 years follow-up
At study end (median 11.1 years of follow-up)
…=Not Reported